Background
Host defence peptide (HDP) has multiple properties [1, 2] potentiating it as a novel anticancer agent. However disadvantages include systemic toxicity [3]. To address this, a prodrug was developed and the aim was to assess toxicity differentials between this prodrug and its active peptide component on T84 colonic carcinoma cells. Prodrug bio activation mechanism was also assessed by use of a Cathepsin B inhibitor.